Susquehanna International Group
ATXI

Susquehanna International Group’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Susquehanna International Group’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-959
Closed -$10.6K – 13444
2024
Q1 		$10.6K Buy
+959
New +$11.4K ﹤0.01% 11901
2022
Q3 		– Sell
-23
Closed -$7K – 14305
2022
Q2 		$7K Buy
+23
New +$8.86K ﹤0.01% 12577
2020
Q2 		– Sell
-18
Closed -$181K – 11103
2020
Q1 		$181K Buy
+18
New +$180K ﹤0.01% 8804

Other funds holding ATXI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group's ATXI Position: Q2 2024 in Review

Susquehanna International Group sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2024, closing a stake of 959 shares — an estimated $10.6K sold.

Susquehanna International Group first reported a position in ATXI in Q1 2020 and held it in 3 quarters. The position peaked at $181K in Q1 2020. 9 funds tracked by Wall St. Rank hold ATXI as of Q2 2024.

  • Susquehanna International Group reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Susquehanna International Group sold 959 Avenue Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $10.6K.
  • Susquehanna International Group first reported a position in Avenue Therapeutics, Inc. Common Stock in Q1 2020 and held it in 3 quarters.
  • Susquehanna International Group's Avenue Therapeutics, Inc. Common Stock position peaked at $181K in Q1 2020.
  • 9 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.